| Literature DB >> 22348147 |
Gunapala Shetty1, Paul B Comish, Connie C Y Weng, Angabin Matin, Marvin L Meistrich.
Abstract
The prevalence of testicular germ cell tumors (TGCT), a common solid tissue malignancy in young men, has been annually increasing at an alarming rate of 3%. Since the majority of testicular cancers are derived from germ cells at the stage of transformation of primordial germ cell (PGC) into gonocytes, the increase has been attributed to maternal/fetal exposures to environmental factors. We examined the effects of an estrogen (diethylstilbestrol, DES), an antiandrogen (flutamide), or radiation on the incidence of testicular germ cell tumors in genetically predisposed 129.MOLF-L1 (L1) congenic mice by exposing them to these agents on days 10.5 and 11.5 of pregnancy. Neither flutamide nor DES produced noticeable increases in testis cancer incidence at 4 weeks of age. In contrast, two doses of 0.8-Gy radiation increased the incidence of TGCT from 45% to 100% in the offspring. The percentage of mice with bilateral tumors, weights of testes with TGCT, and the percentage of tumors that were clearly teratomas were higher in the irradiated mice than in controls, indicating that irradiation induced more aggressive tumors and/or more foci of initiation sites in each testis. This radiation dose did not disrupt spermatogenesis, which was qualitatively normal in tumor-free testes although they were reduced in size. This is the first proof of induction of testicular cancer by an environmental agent and suggests that the male fetus of women exposed to radiation at about 5-6 weeks of pregnancy might have an increased risk of developing testicular cancer. Furthermore, it provides a novel tool for studying the molecular and cellular events of testicular cancer pathogenesis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22348147 PMCID: PMC3278464 DOI: 10.1371/journal.pone.0032064
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Breeding efficiency in 129.MOLF-L1 congenic mice with or without in utero flutamide, DES, or radiation treatment.
| Treatment | Plug positive | Produced progeny | Litter size |
| Control | 48 | 19 (40%) | 4.9±0.3 |
| Flutamide | 36 | 23 (64%) | 5.1±0.6 |
| Control | 5 | 3 (60%) | 4.6±0.3 |
| DES | 12 | 6 (50%) | 4.5±0.7 |
| Control | ND | ND | 6.4±0.7 |
| Radiation | 28 | 15 (54%) | 5.3±0.6 |
Values given as absolute number and percentage of total plug-positive females.
Mean ± SEM.
Figure 1Morphology and histology of the testes in 4-week-old 129.MOLF-L1 male mice irradiated in utero with two doses of 0.8 Gy and controls.
Testicular morphology showing bilateral (A) and unilateral (B) TGCTs from irradiated mice. Note that the testis without TGCT after in utero radiation exposure (B) is smaller than the normal untreated testis from a 4-week-old mouse (insert in B). Testis sections showing teratoma containing tissues apparently from multiple dermal origins identified by morphology (C), and TGCT containing only neuroepithelial cells (NE) (D). CA: cartilage; BM: bone marrow; MS: muscle, EEP: endodermal epithelium. ST: seminiferous tubule; BV: blood vessel. Sections from testes of 4-week old irradiated (E) and contol (F) mice without TGCT showing qualitatively normal spermatogenesis. Bar: 0.5 cm in A & B, and 50 µm in C–F.
Testicular germ cell tumor (TGCT) incidence and related characterization in 129.MOLF-L1 congenic mice with or without in utero flutamide, DES, or radiation treatment.
| Treatment | No. males analyzed | Overall TGCT | Bilateral TGCT | No. testes analyzed | TGCT | % identified as teratomas | Weight (mg) | Weight (mg) |
| Control | 54 | 21 (39%) | 2 (4%) | 108 | 23 (21%) | 15 (65%) | 50±1 (n = 84) | 96±14 (n = 22) |
| Flutamide | 51 | 24 (47%) | 7 (14%) | 102 | 31 (30%) | 27 (87%) | 49±1 (n = 55) | 109±18 (n = 25) |
| Control | 5 | 1 (20%) | 0 (0%) | 10 | 1 (10%) | 0 (0%) | 46±2 (n = 9) | 58 (n = 1) |
| DES | 12 | 2 (17%) | 1 (8%) | 24 | 3 (13%) | 3 (100%) | 47±2 | 161±93 (n = 3) |
| Control | 20 | 9 (45%) | 2 (10%) | 40 | 11 (28%) | 7 (64%) | 60±1 (n = 30) | 76±9 (n = 10) |
| Radiation | 23 | 23 (100%) | 14 (61%) | 46 | 37 (80%) | 35 (95%) | 36±1 | 158±28 |
Mean ± SEM.
Values given as absolute number and percentage of mice, testes, or tumors analyzed.
Since the incidence of tumors in the DES-treated mice was not increased from historical controls or the concurrent flutamide controls, we did not complete this arm of the study, and cannot rigorously conclude that there is no increase in tumor incidence in DES-treated mice compared to a sham-treated control group.
Two cryptorchid testes (weights, 19 and 34 mg) were excluded from this average.
Significantly different between treated and control mice, Fisher's exact Chi square test: P<0.01. Other differences were not significant (P≥0.05).
Significantly different between treated and control mice, t test: P<0.01. Other differences were not significant (P≥0.05).